These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35358582)

  • 1. Therapeutic targeting of TANK-binding kinase signaling towards anticancer drug development: Challenges and opportunities.
    Alam M; Ansari MM; Noor S; Mohammad T; Hasan GM; Kazim SN; Hassan MI
    Int J Biol Macromol; 2022 May; 207():1022-1037. PubMed ID: 35358582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review on the role of TANK-binding kinase 1 signaling in cancer.
    Alam M; Hasan GM; Hassan MI
    Int J Biol Macromol; 2021 Jul; 183():2364-2375. PubMed ID: 34111484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of TBK1 Inhibition in Targeted Therapy of Cancer.
    Yang X; Liu Z
    Mini Rev Med Chem; 2024; 24(10):1031-1045. PubMed ID: 38314681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting TANK-binding kinase 1 (TBK1) in cancer.
    Revach OY; Liu S; Jenkins RW
    Expert Opin Ther Targets; 2020 Nov; 24(11):1065-1078. PubMed ID: 32962465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of TBK1 in cancer pathogenesis and anticancer immunity.
    Runde AP; Mack R; S J PB; Zhang J
    J Exp Clin Cancer Res; 2022 Apr; 41(1):135. PubMed ID: 35395857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.
    Cheng C; Ji Z; Sheng Y; Wang J; Sun Y; Zhao H; Li X; Wang X; He Y; Yao J; Wang L; Zhang C; Guo Y; Zhang J; Gao WQ; Zhu HH
    Theranostics; 2018; 8(17):4633-4648. PubMed ID: 30279728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BX795, a TBK1 inhibitor, exhibits antitumor activity in human oral squamous cell carcinoma through apoptosis induction and mitotic phase arrest.
    Bai LY; Chiu CF; Kapuriya NP; Shieh TM; Tsai YC; Wu CY; Sargeant AM; Weng JR
    Eur J Pharmacol; 2015 Dec; 769():287-96. PubMed ID: 26607461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TBK1 inhibitors: a review of patent literature (2011 - 2014).
    Yu T; Yang Y; Yin DQ; Hong S; Son YJ; Kim JH; Cho JY
    Expert Opin Ther Pat; 2015; 25(12):1385-96. PubMed ID: 26293650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of High-Affinity Inhibitors of TANK-Binding Kinase 1 (TBK1): A Promising Frontier for Controlling Inflammatory Signaling in Cancer.
    Jairajpuri DS; Mohammad T; Hussain A; Alajmi MF; Yadav DK; Hassan MI
    Discov Med; 2024 Jan; 36(180):129-139. PubMed ID: 38273753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TANK-binding kinase 1 mediates osteoclast differentiation by regulating NF-κB, MAPK and Akt signaling pathways.
    Lin S; Zhao XL; Wang Z
    Immunol Cell Biol; 2021 Feb; 99(2):223-233. PubMed ID: 32896936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation.
    Clark K; Plater L; Peggie M; Cohen P
    J Biol Chem; 2009 May; 284(21):14136-46. PubMed ID: 19307177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of TBK1 by amlexanox attenuates paraquat-induced acute lung injury.
    Wang N; Li Y; Wang X; Ma Z; Wang Y; Zhang C; Yuan Y; Zhao M
    Toxicology; 2020 Oct; 443():152555. PubMed ID: 32763286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting TBK1 attenuates ocular inflammation in uveitis by antagonizing NF-κB signaling.
    Chen S; Kong J; Wu S; Luo C; Shen J; Zhang Z; Zou J; Feng L
    Clin Immunol; 2023 Jan; 246():109210. PubMed ID: 36528252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase.
    Pomerantz JL; Baltimore D
    EMBO J; 1999 Dec; 18(23):6694-704. PubMed ID: 10581243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-κB activation through TBK1.
    Abe T; Barber GN
    J Virol; 2014 May; 88(10):5328-41. PubMed ID: 24600004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies.
    Hasan M; Yan N
    Pharmacol Res; 2016 Sep; 111():336-342. PubMed ID: 27353409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TANK-binding kinase 1 (TBK1) modulates inflammatory hyperalgesia by regulating MAP kinases and NF-κB dependent genes.
    Möser CV; Stephan H; Altenrath K; Kynast KL; Russe OQ; Olbrich K; Geisslinger G; Niederberger E
    J Neuroinflammation; 2015 May; 12():100. PubMed ID: 25997745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The non-canonical IκB kinases IKKε and TBK1 as potential targets for the development of novel therapeutic drugs.
    Niederberger E; Möser CV; Kynast KL; Geisslinger G
    Curr Mol Med; 2013 Aug; 13(7):1089-97. PubMed ID: 23157677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
    Thomson DW; Poeckel D; Zinn N; Rau C; Strohmer K; Wagner AJ; Graves AP; Perrin J; Bantscheff M; Duempelfeld B; Kasparcova V; Ramanjulu JM; Pesiridis GS; Muelbaier M; Bergamini G
    ACS Med Chem Lett; 2019 May; 10(5):780-785. PubMed ID: 31097999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.